Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2α dephosphorylation and its phosphomimetic S51D variant.

Saved in:

Bibliographic Details
Title:	Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2α dephosphorylation and its phosphomimetic S51D variant.
Authors:	Eytan K; Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel., Versano Z; Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Oren R; Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, Israel., Jacob-Hirsch J; Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel.; Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel., Leitner M; Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel., Harmelin A; Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, Israel., Rechavi G; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel.; Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel., Toren A; Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Paglin S; Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel., Yalon M; Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel.; Chaim Sheba Medical Center, Ramat Gan, Israel.
Source:	Frontiers in oncology [Front Oncol] 2022 Aug 26; Vol. 12, pp. 959133. Date of Electronic Publication: 2022 Aug 26 (Print Publication: 2022).
Publication Type:	Journal Article
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2234-943X
DOI:	10.3389/fonc.2022.959133